[go: up one dir, main page]

WO1999040929A1 - Procedes de potentialisation des cancerotherapies - Google Patents

Procedes de potentialisation des cancerotherapies Download PDF

Info

Publication number
WO1999040929A1
WO1999040929A1 PCT/US1999/003083 US9903083W WO9940929A1 WO 1999040929 A1 WO1999040929 A1 WO 1999040929A1 US 9903083 W US9903083 W US 9903083W WO 9940929 A1 WO9940929 A1 WO 9940929A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
mammal
relaxin
therapy
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/003083
Other languages
English (en)
Inventor
Brian Seed
Rakesh K. Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to US09/601,919 priority Critical patent/US6719977B1/en
Publication of WO1999040929A1 publication Critical patent/WO1999040929A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins

Definitions

  • This invention relates to anti-cancer therapy, particularly for the treatment of solid rum.
  • Cancer accounts for one fifth of the total mortality in the United States and is the second leading cause of death.
  • One effective anti-cancer therapy is chemotherapy.
  • solid tumors e.g., tumors in the lung, colon, and breast
  • efficient treatment is hindered by the difficulty in penetrating the tumor mass with anti-cancer agents (Jain, Sci. Amer. 271 : 58-65, 1994).
  • the identification of a means by which to facilitate the delivery of therapeutic agents to the cancer site would enhance the effectiveness of anti-cancer therapies.
  • the invention features a method for treating a cancer in a mammal that involves administering relaxin and an anti-cancer therapy to the mammal, the relaxin and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the relaxin is administered either prior to the administration of the anti-cancer therapy or simultaneously with the administration of the anti-cancer therapy.
  • the method further involves administration of ⁇ -interferon.
  • the invention features a method for treating a cancer in a -2- mammal that involves administering ⁇ -interferon and an anti-cancer therapy to the mammal, the ⁇ -interferon and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the ⁇ -interferon is administered either prior to the administration of the anti-cancer therapy or simultaneously with the administration of the anti-cancer therapy.
  • the method further involves administration of relaxin.
  • the anti-cancer therapy includes a biotherapeutic agent, for example, a chemotherapeutic agent.
  • the mammal is a human; and the cancer is a solid tumor, for example, a solid tumor in a tissue selected from the group consisting of brain, kidney, liver, nasopharyngeal cavity, thyroid, skin, central nervous system, ovary, breast, prostate, colon, rectum, uterus, cervix, endometrium, lung, bladder, pancreas, and lymph node.
  • the invention features a method for treating a cancer in a mammal that involves administering to the mammal a tissue tensile modulus-reducing compound and an anti-cancer therapy, the compound and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the invention features a method for treating a cancer in a mammal that involves administering to the mammal a compound that reduces the interstitial viscosity of the cancer and an anti-cancer therapy, the compound and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the invention features a method for treating a cancer in a mammal that involves administering to the mammal a compound that increases the hydraulic conductance of the cancer and an anti-cancer therapy, the -3- compound and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the invention features a method for treating a cancer in a mammal that involves administering to the mammal a compound that increases collagen turnover or decreases collagen formation at or near the cancer and an anti- cancer therapy, the compound and the anti-cancer therapy being administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.
  • the anti-cancer therapy includes a biotherapeutic agent, for example, a chemotherapeutic agent; the mammal is a human; the cancer is a solid tumor; and the compound is either relaxin or ⁇ -interferon, or both.
  • a biotherapeutic agent for example, a chemotherapeutic agent
  • the mammal is a human
  • the cancer is a solid tumor
  • the compound is either relaxin or ⁇ -interferon, or both.
  • cancer or “neoplasm” is meant any abnormal proliferation of cells, which may be benign or malignant, and which includes solid tumors.
  • Solid tumors may occur in a variety of tissues including, without limitation, the brain, kidney, liver, nasopharyngeal cavity, thyroid, skin, central nervous system, ovary, breast, prostate, colon, rectum, uterus, cervix, endometrium, lung, bladder, pancreas, and lymph node.
  • anti-cancer therapy is meant any therapy that destroys a cancer cell, or slows, arrests, or reverses the growth of a cancer cell.
  • Anti-cancer therapies include, without limitation, radiation therapy (radiotherapy), chemotherapy, or a combination of these therapies.
  • chemotherapy is meant the use of a chemical agent to destroy a cancer cell, or to slow, arrest, or reverse the growth of a cancer cell.
  • biotherapeutic agent is meant a substituted or unsubstituted peptide, polypeptide, virus, cell, glycan, or combination thereof, which may be used to destroy a cancer cell, or to slow, arrest, or reverse the growth of a cancer cell.
  • chemotherapeutic agent is meant a chemical that may be used to destroy a -4- cancer cell, or to slow, arrest, or reverse the growth of a cancer cell.
  • Chemotherapeutic agents include, without limitation, asparaginase, bleomycin, busulfan carmustine (commonly referred to as BCNU), chlorambucil, cladribine (commonly referred to as 2-CdA), CPT-11 , cyclophosphamide, cytarabine (commonly referred to as Ara-C), dacarbazine, daunorubicin, dexamethasone, doxorubicin (commonly referred to as Adriamycin), etoposide, fludarabine, 5-fluorouracil (commonly referred to as 5FU), hydroxyurea, idarubicin, ifosfamide, interferon- (native or recombinant), levamisole, lomustine (commonly referred to
  • responsive is meant that a cell is destroyed by an anti-cancer therapy, or that the growth of a cell is slowed, arrested, or reversed by an anti-cancer therapy.
  • the growth may be measured by any standard technique including, for example, cell count, measurement with calipers, or weight.
  • the growth of the cancer is reversed such that the cancer is at least 50% smaller than the cancer prior to therapy. Most preferably, the cancer is destroyed by the therapy.
  • tissue tensile modulus-reducing compound a compound that reduces the tensile modulus (i.e., the Young's modulus, or the coefficient of the strain in the linear stress to strain relation) of tissue deformed by the presence of a cancer.
  • a significant obstacle to the delivery of anti-cancer agents, and particularly chemotherapeutic agents, to solid tumors is the tumor hydrostatic environment.
  • the -5- tumor core has a high internal pressure, and the tumor interstitium is highly viscous. Together these effects form a barrier to conduction of small and large molecules from the plasma into the tumor.
  • the high central pressure in the tumor is resisted by elastic forces generated in the surrounding tissue and from within the tumor itself.
  • the tumor generates pressure, presumably by uncontrolled proliferation, which acts both upon the tumor constituents and the surrounding normal but deformed tissue.
  • the elastic forces and the pressure balance, and the tumor neither expands nor shrinks on a rapid time scale.
  • the present invention involves the administration of relaxin and/or ⁇ -IFN peptides, and thereby improves anti-cancer therapeutic approaches.
  • a reduction in the tissue tensile modulus might be expected to facilitate tumor growth by decreasing mechanical resistance to cellular proliferation and spread.
  • this would be considered undesirable, in the context of chemotherapy, decreased tumor pressure and facilitated tumor growth are expected to enhance the cytotoxic potential of existing anti-neoplastic agents, nearly all of which are directed at killing rapidly proliferating cells.
  • relaxin With respect to relaxin, it has been demonstrated that in at least one experimental setting, namely, the stretching of skin by an implanted subcutaneous balloon, that the pressure- volume relationship for the expansion of the fluid-filled -6- balloon could be altered by the infusion of relaxin. In this case, the administration of relaxin decreased the resistance to balloon expansion. Thus relaxin has, over a period of time, the capacity to decrease the modulus of skin and underlying connective tissue.
  • High tumor interstitial viscosity is another important consideration for the effective delivery of chemotherapeutic agents.
  • the diffusion coefficient of molecules in liquids is inversely related to the viscosity of the solvent. Increasing viscosity thus retards diffusion of plasma-borne drugs into the tumor interstitium.
  • a recent unexpected finding has been that interstitial viscosity is strongly influenced by the presence of collagen, and that infusion of collagenase dramatically facilitates penetration of small and large molecules into a tumor.
  • the methods of the present invention further facilitate the delivery of anti- cancer therapeutics by also reducing interstitial viscosity and increasing hydraulic conductance of tumors through a decrease in the presence and/or concentration of collagen.
  • relaxin has been shown to prevent the formation of fibrotic capsules surrounding impenetrable foreign bodies, the accumulation of collagen within implanted sponges, and the parenchymal fibrosis that accompanies oxidative pulmonary damage induced by the chemotherapeutic agent bleomycin.
  • ⁇ -interferon a pleiotypic cytokine produced by helper T cells
  • bFGF basic fibroblast growth factor
  • the present invention makes use of these characteristics of relaxin and ⁇ -IFN to potentiate anti-cancer therapies. Because both relaxin and ⁇ -IFN act as anti-fibrotic agents which have the capacity to reduce collagen and matrix accumulation, and to accelerate matrix turnover, administration of these peptides are useful for reducing tumor pressure and decreasing interstitial viscosity, effects which facilitate the penetration of cytotoxic agents into tumors. Thus, the delivery of relaxin, ⁇ -IFN, or relaxm plus ⁇ -IFN, may be utilized to potentiate the effects of anti-cancer agents. Of the two peptides, relaxin is expected to affect existing collagenous matrix, whereas ⁇ - IFN is likely to retard the formation of new tumor stroma from existing fibroblasts. As a result, the action of relaxin is likely to be more rapid.
  • these anti-fibrotic peptide hormones are likely to be most effective if provided in advance of the anti-neoplastic agent, to condition the tumor bed for more effective drug delivery.
  • the timing of the relaxin and/or ⁇ -IFN treatment should be adjusted to optimize tumor susceptibility without allowing excessive tumor growth. Because relaxin is known to exert its effects relatively rapidly (essentially immediately for protection against an acute fibrotic insult), a preferable treatment regimen involves initiation of relaxin and/or ⁇ - IFN treatment within a few days prior to the first round of therapy, and continuation of one or both of these peptides for the duration of the therapy. -8-
  • chemotherapeutic agents include, without limitation, alkylating agents, nitrosoureas, anti-metabolites, plant alkaloids, antitumor antibiotics, and steroid hormones.
  • Alkylating agents are useful chemotherapeutics that kill cells by directly attacking DNA, and may be used, according to the invention, in the treatment of, for example, chronic leukemias, Hodgkin's disease, lymphomas, and certain carcinomas of the lung, breast, prostate, and ovary.
  • One commonly used alkylating agent is cyclophosphamide.
  • Nitrosourea drugs are also useful chemotherapeutics of the invention which, being able to cross the blood-brain barrier, may be used, for example, to treat brain tumors, as well as lymphomas, multiple myeloma, and malignant melanoma.
  • Drugs of this category to which carmustine (BCNU) and lomustine (CCNU) belong, act similarly to akylating agents and, additionally, inhibit changes necessary for DNA repair.
  • anti-metabolite category which includes drugs that block cell growth by interfering with certain activities during the "S" phase of the cell cycle, usually DNA synthesis.
  • anti-metabolites halt normal development and -9- reproduction, and are useful, for example, for the treatment of acute and chronic leukemias, choriocarcinoma, and tumors of the gastrointestinal tract, breast, and ovary.
  • Examples of commonly used anti-metabolites are 6-mercaptopurine and 5-fluorouracil (5FU).
  • Plant (vinca) alkaloids are plant-derived anti-tumor agents which may also be exploited in the methods of the invention, and include vincristine and vinblastine.
  • These agents which act specifically by blocking cell division during mitosis, are commonly used in the treatment of acute lymphoblastic leukemia, Hodgkin's and non-Hodgkin's lymphomas, neuroblastomas, Wilms' tumor, and cancers of the lung, breast, and testes.
  • Antitumor antibiotics are another diverse group of compounds that may be used in the methods of the invention and that, in general, act by binding with DNA and preventing RNA synthesis. These agents may be used for the treatment of a variety of cancers, and include doxorubicin (Adriamycin), mitomycin-C, and bleomycin. Steroid hormones, or hormone antagonists, may also be used as chemotherapeutic agents, given their abilities to modify the growth of certain hormone-dependent cancers. This class includes adrenocorticosteroids, estrogens, anti-estrogens, progesterones, and androgens. One example of a steroid hormone antagonist is tamoxifen, a drug used for estrogen-dependent breast cancer. In addition to the above, any other chemotherapeutic agent may be used in the methods of the invention, including other anti-neoplastic agents whose mechanisms of action do not permit broad categorization.
  • relaxin and ⁇ -IFN may be administered systemically, for example, formulated in a pharmaceutically-acceptable buffer such as physiological saline.
  • a pharmaceutically-acceptable buffer such as physiological saline.
  • routes of administration include, for -10- example, intravenous, subcutaneous, intramuscular, or intradermal injections which provide continuous, sustained levels of the drug in the patient.
  • relaxin and/or ⁇ -IFN may be given to a patient by injection of a slow release preparation, slowly dissociating polymeric form, or crystalline form; this sort of sustained administration may follow an initial delivery of the drug by more conventional routes (for example, those described above).
  • relaxin and ⁇ -IFN may be administered using an infusion pump, thus allowing a precise degree of control over the rate of drug release, or through instillation of relaxin and ⁇ -IFN in the nasal passages in a similar fashion to that used to promote abso ⁇ tion of insulin.
  • relaxin and ⁇ -IFN may be delivered by aerosol deposition of a powder or solution into the lungs.
  • Relaxin and ⁇ -IFN may also be administered locally to achieve substantial chemotherapy-enhancing outcomes. Since the desired action of the agent is generally upon a circumscribed mass of tissue proximal to a specific cancer, delivery of the peptide by means which promote high local concentrations in the vicinity of the cancer may be especially desirable. For this reason, injection of the agent into tissue sites adjacent to, or upstream of the draining circulation of, the affected site is preferable. Alternatively, in conditions involving deep organ structures, for example, in the displacement of tissue by invasive tumors, implantation of sustained release formulations of relaxin and/or ⁇ -IFN (such as osmotic pumps or erodable polymeric compositions impregnated with the hormone) near the affected tumor site may be preferred.
  • sustained release formulations of relaxin and/or ⁇ -IFN such as osmotic pumps or erodable polymeric compositions impregnated with the hormone
  • Chemotherapeutic Agents with Relaxin and ⁇ -IFN The most common routes of administration for chemotherapy are oral, -11- intravenous, and intramuscular. More recently, other methods have been used to increase the local concentration of chemotherapeutic agents at a tumor site. For example, if the cancer occurs in an ami or leg. chemotherapy may be administered by arterial perfusion, delivering the chemotherapeutic agent directly into the bloodstream of the arm or leg where the cancer is found. Chemotherapy can also be administered directly into a specific cavity (intracavitary), the abdomen (intraperitoneal), the lung (intrapleural), or the central nervous system (intrathecal), or may be applied directly to the skin (topical). If desired, relaxin and/or ⁇ -IFN may be administered by the same route as the chemotherapeutic agent, even if relaxin and/or ⁇ -IFN and the chemotherapeutic agent are not administered simultaneously.
  • Relaxin for either systemic or local administration, may be obtained from Connectics Corporation (Palo Alto, CA), or may be synthesized either by standard techniques of recombinant polypeptide production (see, e.g., Ausubel et al, Current Protocols in Molecular Biology. John Wiley & Sons, New York, 1997; Sambrook et al, Molecular Cloning. A Laboratory Manual. 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989) or by peptide synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis. 2nd ed., 1984 The Pierce Chemical Co., Rockford, IL).
  • Relaxin gene and peptide sequences are provided, e.g., in Hudson et al, Nature 301 :628-631, 1983; Hudson et al, EMBO J. 3:2333-2339, 1984; and Gunnersen et al, J. Mol. Endocrinol. 15: 153-166, 1995.
  • relaxin polypeptide native to a species will be preferred for therapeutic administration.
  • relaxin fragments or analogs shown to be functional e.g., in the bioassays of Fei et al. (Biochem. Biophys. Res. Comm. 170:214-222, 1990) and Kramer et al. (In Nitro Cell. Dev. Biol. 26:647-656, 1990), and in the mouse pubic symphysis assay (Bullesbach and Schwabe, Biochemistry 25: -12-
  • Particularly preferred relaxin fragments include the B29 relaxin fragment described by Winslow et al. (Proc. 71st Meeting of Endocrine Society 889 Abstract, 1989), Bryant-Greenwood, D. G., Molecular and Cellular Endocrinology 79: C125-C132, 1991), and Bullesbach and Schwabe (Biochemistry 24: 7717-7722,1985).
  • Particularly preferred relaxin analogs include polypeptides which differ from a native relaxin polypeptide only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, aspartic acid for glutamic acid, etc.).
  • Other preferred analogs include relaxin polypeptides which are modified for the purpose of increasing peptide stability; such analogs may contain, e.g., one or more desaturated peptide bonds or D-amino acids in the peptide sequence or may be formulated as cyclized peptide molecules.
  • a prorelaxin polypeptide see, e.g., Hudson et al, EMBO J. 3:2333, 1984; and Nu et al, Life Sci. 52:1055, 1993
  • a prorelaxin polypeptide may be administered as a chemotherapy-enhancing reagent according to the invention.
  • ⁇ -Interferon ( ⁇ -IF ⁇ ) ⁇ -IF ⁇ for either systemic or local administration, may also be obtained from any commercially available source (e.g., Sigma- Aldrich Chemical Co., St, Louis, MO), or may be synthesized either by standard techniques of recombinant polypeptide production or by peptide synthesis, as described above.
  • ⁇ -IF ⁇ gene and peptide sequences are provided, e.g., in Taya et al, EMBO J. 1 : 953-958, 1982; Gray et al, Nature 295 : 503-508, 1982; Gray and Goeddel, Nature 298: 859-863, 1982; Devos et al, Nucleic Acids Res.
  • ⁇ -IFN polypeptide native to a species will be preferred for therapeutic administration.
  • ⁇ -IFN fragments or analogs shown to be functional may also be administered as chemotherapy-enhancing reagents according to the invention.
  • Preferred ⁇ -IFN analogs include polypeptides which differ from a native ⁇ -IFN polypeptide only by conservative amino acid substitutions, and ⁇ -IFN polypeptides which are modified for the purpose of increasing peptide stability.
  • Dosages of Relaxin and ⁇ -IFN Relaxin is administered systemically at a dosage that provides an enhancement of the cancer cell-inhibiting effects of a chemotherapeutic agent.
  • Dosages of relaxin are typically administered to result in a blood serum concentration that is between 0.1- 100 nanograms/ml, preferably between 1-10 nanograms/ml, and may be administered with the appropriate dosage of the chemotherapeutic agent with or without ⁇ -IFN. Because administration of the relaxin polypeptide may promote loosening of connective tissues, it may be desirable, where possible, to encourage muscular development through physical therapy to counteract any excessive loosening observed during the course of relaxin treatment.
  • ⁇ -IFN is also administered systemically at a dosage that provides an enhancement of the cancer cell-inhibiting effects of a chemotherapeutic agent.
  • Dosages of ⁇ -IFN are typically between 0.01 and 10 mg/sq. meter body surface area (Kopp et al, J Immunother. 13: 181-190, 1993; Bolinger and Taeubel, Clin. Pharm. 11 : 834-850, 1992), and may be administered with a chemotherapeutic agent with or without co-administration of relaxin.
  • Relaxin and/or ⁇ -IFN may be administered simultaneously with the chemotherapeutic agent or, as described above, a few days prior to the initiation of -14- admini strati on of the chemotherapeutic agent. Where local administration schemes are employed, the concentrations of relaxin in the affected tissue may substantially exceed the levels described above.
  • the methods of the invention may be used to potentiate anti-cancer therapies in any mammal, for example, humans, domestic pets, or livestock.
  • the relaxin and/or ⁇ -IFN employed is preferably specific for that species (e.g., for pigs, see Haley et al, DNA 1 :155, 1982; and Vandenbroeck et al, Biochem. Biophys. Res. Commun. 180: 1408-1415, 1991) All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne différents procédés de potentialisation des propriétés curatives en cancérothérapie chez un mammifère, qui consistent à administrer au mammifère, simultanément à la thérapie, un composé (du type relaxine ou interféron η-IFN) ayant une propriété de réduction de module d'élasticité tissulaire en traction, une capacité de réduction de la viscosité interstitielle du cancer, une capacité d'augmentation de la conductance hydraulique du cancer, ou bien une capacité d'augmentation du renouvellement du collagène ou de diminution de la formation du collagène à l'emplacement du cancer ou près de cet emplacement. On dose la thérapie et le composé de sorte que la combinaison des deux suffise à annihiler, ralentir ou interrompre le cancer. L'invention concerne également un procédé relatif au traitement du cancer chez un mammifère, qui consiste à administrer les peptides du type relaxine et/ou ηIFN simultanément à la cancérothérapie, en respectant des doses qui, dans la combinaison des deux, suffisent à annihiler, ralentir ou interrompre le cancer.
PCT/US1999/003083 1998-02-12 1999-02-11 Procedes de potentialisation des cancerotherapies Ceased WO1999040929A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/601,919 US6719977B1 (en) 1998-02-12 1999-02-11 Methods to potentiate cancer therapies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450298P 1998-02-12 1998-02-12
US60/074,502 1998-02-12

Publications (1)

Publication Number Publication Date
WO1999040929A1 true WO1999040929A1 (fr) 1999-08-19

Family

ID=22119898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003083 Ceased WO1999040929A1 (fr) 1998-02-12 1999-02-11 Procedes de potentialisation des cancerotherapies

Country Status (1)

Country Link
WO (1) WO1999040929A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326627A4 (fr) * 2000-10-04 2004-06-16 Molecular Medicine Res Inst Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine
EP1399537A4 (fr) * 2001-04-03 2006-09-06 Curagen Corp Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation
JP2007531519A (ja) * 2004-03-30 2007-11-08 インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物
US7833526B2 (en) 2000-10-04 2010-11-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128126A (en) * 1989-04-11 1992-07-07 Boehringer Ingelheim International Gmbh Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
US5268169A (en) * 1989-02-02 1993-12-07 Roussel Uclaf Treatment method of ovarian cancer using interferon gamma
US5656592A (en) * 1993-09-29 1997-08-12 Seed; Brian Use of relaxin as an analgesic and palliative for intractable pain
US5762921A (en) * 1994-06-16 1998-06-09 Genentech, Inc. Composition and methods for the treatment of tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268169A (en) * 1989-02-02 1993-12-07 Roussel Uclaf Treatment method of ovarian cancer using interferon gamma
US5128126A (en) * 1989-04-11 1992-07-07 Boehringer Ingelheim International Gmbh Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
US5656592A (en) * 1993-09-29 1997-08-12 Seed; Brian Use of relaxin as an analgesic and palliative for intractable pain
US5762921A (en) * 1994-06-16 1998-06-09 Genentech, Inc. Composition and methods for the treatment of tumors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002919179, Database accession no. 124-139978X *
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002919180, Database accession no. 120-69026B *
HAND A, ET AL.: "INTERFERON (IFN)-ALPHA AND IFN-GAMMA IN COMBINATION WITH METHOTREXATE: IN VITRO SENSITIVITY STUDIES IN FOUR HUMAN MESOTHELLOMA CELL LINES", ANTI-CANCER DRUGS, LIPPINCOTT WILLIAMS & WILKINS, US; NL, vol. 06, 1 January 1995 (1995-01-01), US; NL, pages 77 - 82, XP002919182, ISSN: 0959-4973 *
IIGO M., SHIMIZU I., SAGAWA K.: "SYNERGISTIC ANTITUMOR EFFECTS OF CARBOPLATIN AND INTERFERONS ON HEPATIC METASTASES OF COLON CARCINOMA 26 AND M5076 RETICULUM CELL SARCOMA.", JAPANESE JOURNAL OF CANCER RESEARCH, AMSTERDAM, NL, vol. 84., 1 January 1993 (1993-01-01), NL, pages 794 - 799., XP002919181 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326627A4 (fr) * 2000-10-04 2004-06-16 Molecular Medicine Res Inst Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine
JP2008297313A (ja) * 2000-10-04 2008-12-11 Molecular Medicine Research Inst レラキシンのアゴニストまたはアンタゴニストの投与によるアポトーシスを調節する方法
US7833526B2 (en) 2000-10-04 2010-11-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US8119136B2 (en) 2000-10-04 2012-02-21 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
JP2012184273A (ja) * 2000-10-04 2012-09-27 Molecular Medicine Research Inst レラキシンのアゴニストまたはアンタゴニストの投与によるアポトーシスを調節する方法
US9534034B2 (en) 2000-10-04 2017-01-03 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1399537A4 (fr) * 2001-04-03 2006-09-06 Curagen Corp Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation
JP2007531519A (ja) * 2004-03-30 2007-11-08 インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物
EP1729817A4 (fr) * 2004-03-30 2008-07-09 Ind Academic Coop Systeme de delivrance de gene contenant le gene de la relaxine et composition pharmaceutique utilisant la relaxine
JP4764872B2 (ja) * 2004-03-30 2011-09-07 インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物
CN1968717B (zh) * 2004-03-30 2013-08-21 延世大学教产学协力团 含有松弛素基因的基因送递系统和使用松弛素的药物组合物

Similar Documents

Publication Publication Date Title
JP4220235B2 (ja) 短期及び長期の薬剤薬量決定のための方法
US6719977B1 (en) Methods to potentiate cancer therapies
Kvols Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy
US20090035270A1 (en) COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha
CA2489323A1 (fr) Prevention et traitement d'une steatose hepatique non alcoolique (nafld), par antagonisme du recepteur du polypeptide insulinotropique gluco-dependant (gip)
WO1992013556A1 (fr) Combinaison d'igf-i et d'igfbp pour favoriser l'anabolisme
CA2460690A1 (fr) Procede de traitement de l'infection par le virus de l'hepatite au moyen d'un profil de diffusion d'interferon multiphasique
US20100330093A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
CA2708168A1 (fr) Traitement d'un melanome avec des peptides alpha thymosine en combinaison avec un activateur d'apoptose de choc thermique antineoplasique (hsaa)
WO1999040929A1 (fr) Procedes de potentialisation des cancerotherapies
JP2009539916A (ja) ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用
US7018979B1 (en) Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2005509647A (ja) エストロゲン応答性乳癌の治療方法
WO2024189056A1 (fr) Régime d'administration d'annexine a1
JP2007169300A (ja) 進行癌の処置のためのテモゾロミドとα−ＩＦＮの組合せ
Stangelberger et al. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207
Hanssen et al. Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report
CA2643529C (fr) Methode et composition permettant d'ameliorer la fonction erectile masculine
Chi et al. In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats
Danoff et al. Somatostatin analogs as primary medical therapy for acromegaly
Bajetta et al. Medical treatment of neuroendocrine tumors
WO2024189054A1 (fr) Dosage retardé de l'annexine a1
Bocci et al. The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients
CN105412916B (zh) 治疗乳腺癌的组合物及其用途
Young et al. Naloxone‐Responsive Hypotension in a Patient with an ACTH‐Secreting Tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09601919

Country of ref document: US

122 Ep: pct application non-entry in european phase